AbbVie Inc (ABBV)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $521.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
AbbVie Inc (ABBV) Financials: Revenue, Profit and Cash Flow
AbbVie reported revenue of $61.16B for the fiscal year ended Dec 31, 2025, up 8.6% from the year before. That year, net income was $4.23B with a net margin of 6.9%, operating cash flow was $19.03B and free cash flow was $17.82B. The quarter ended Sep 30, 2026 had revenue of $17.40B and net income of $4.22B.
Revenue and Margins
The operating margin was 24.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $25.64B, a compound annual rate of 10.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $61.16B | +8.6% | 62.0% | 24.6% | 6.9% |
| Dec 2024 | $56.33B | +3.7% | 70.0% | 16.2% | 7.6% |
| Dec 2023 | $54.32B | -6.4% | 62.4% | 23.5% | 9.0% |
| Dec 2022 | $58.05B | +3.3% | 68.8% | 31.2% | 20.4% |
| Dec 2021 | $56.20B | +22.7% | 69.0% | 31.9% | 20.6% |
| Dec 2020 | $45.80B | +37.7% | 63.4% | 24.8% | 10.1% |
| Dec 2019 | $33.27B | +1.6% | 77.6% | 39.0% | 23.7% |
| Dec 2018 | $32.75B | +16.1% | 76.4% | 19.5% | 17.4% |
| Dec 2017 | $28.22B | +10.1% | 75.0% | 33.8% | 18.8% |
| Dec 2016 | $25.64B | N/A | 77.3% | 36.4% | 23.2% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 1.4% from the year before. In the quarter ended Sep 2026, net income rose 2144.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B |
| Cost of revenue | $23.22B | $16.90B | $20.41B | $18.11B | $17.45B | $16.76B | $7.44B | $7.72B | $7.04B | $5.83B |
| Gross profit | $37.94B | $39.43B | $33.90B | $39.94B | $38.75B | $29.04B | $25.83B | $25.04B | $21.17B | $19.81B |
| Research and development | $9.10B | $12.79B | $7.67B | $6.51B | $6.92B | $6.38B | $6.79B | $10.75B | $5.33B | $4.58B |
| Operating income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B |
| Net income | $4.23B | $4.29B | $4.87B | $11.85B | $11.55B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B |
| EBITDA | $17.36B | $14.26B | $16.63B | $23.99B | $23.89B | $12.15B | N/A | $8.11B | $10.23B | $10.04B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.40B | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B | $14.46B | $12.31B | $14.30B |
| Gross profit | $12.90B | $12.41B | $10.04B | $9.98B | $7.79B | $10.25B | $9.34B | $10.95B | $10.17B | $10.26B | $8.05B | $8.81B |
| Operating income | $6.27B | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | -$1.49B | $3.83B | $4.00B | $2.80B | $3.19B |
| Net income | $4.22B | $3.62B | $697.00M | $1.81B | $188.00M | $941.00M | $1.29B | -$23.00M | $1.56B | $1.37B | $1.37B | $824.00M |
Balance Sheet
As of Dec 2025, total debt of $67.50B exceeded cash and equivalents by $62.27B. Shareholder equity was negative, at -$3.27B, as total liabilities of $137.19B exceeded total assets of $133.96B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B |
| Current assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B | $16.95B | $21.22B | $16.19B |
| Cash and equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B | $9.30B | $5.10B |
| Total liabilities | $137.19B | $131.80B | $124.31B | $121.52B | $131.09B | $137.47B | $97.29B | $67.80B | $65.69B | $61.46B |
| Short-term debt | $8.55B | $6.80B | $7.19B | $4.14B | $12.49B | $8.50B | $3.75B | $5.31B | $6.42B | $402.00M |
| Long-term debt | $58.94B | $60.34B | $52.19B | $59.13B | $64.19B | $77.55B | $62.98B | $49.49B | $46.56B | $44.79B |
| Shareholder equity | -$3.27B | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B | -$8.17B | -$8.45B | $5.10B | $4.64B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $147.68B | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | $134.71B |
| Total liabilities | $152.22B | $141.00B | $143.07B | $137.19B | $136.50B | $137.32B | $134.70B | $131.80B | $137.35B | $135.12B | $140.83B | $124.31B |
| Cash and equivalents | $10.77B | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B | $18.07B | $12.81B |
| Shareholder equity | -$4.58B | -$5.93B | -$6.66B | -$3.23B | -$2.64B | -$183.00M | $1.42B | $3.36B | $6.03B | $6.78B | $8.01B | $10.40B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 93.6% of operating cash flow. Dividends and share repurchases together came to 71.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B | $9.96B | $7.04B |
| Capital expenditures | $1.21B | $974.00M | $777.00M | $695.00M | $787.00M | $798.00M | $552.00M | $638.00M | $529.00M | $479.00M |
| Free cash flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B | $9.43B | $6.56B |
| Dividends paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B |
| Share repurchases | $1.00B | $1.81B | $2.01B | $1.49B | $934.00M | $998.00M | $1.05B | $12.05B | $1.41B | $6.10B |
| Investing cash flow | -$6.64B | -$20.82B | -$2.01B | -$623.00M | -$2.34B | -$37.56B | $596.00M | -$1.01B | -$274.00M | -$6.07B |
| Financing cash flow | -$12.72B | -$5.21B | -$17.22B | -$24.80B | -$19.04B | -$11.50B | $18.71B | -$14.40B | -$5.51B | -$3.93B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.61B | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B | $7.05B | $5.45B | $2.27B | $4.04B | $4.75B |
| Capital expenditures | $301.00M | $322.00M | $265.00M | $329.00M | $381.00M | $269.00M | $235.00M | $291.00M | $249.00M | $241.00M | $193.00M | $205.00M |
| Free cash flow | $7.30B | $3.11B | $3.56B | $4.89B | $6.64B | $4.88B | $1.40B | $6.76B | $5.20B | $2.03B | $3.85B | $4.55B |
Frequently Asked Questions About ABBV
What is AbbVie's annual revenue?
AbbVie reported revenue of $61.16B for the fiscal year ended Dec 31, 2025.
How fast is AbbVie's revenue growing?
Revenue was up 8.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.8%.
Is AbbVie profitable?
Yes. AbbVie reported net income of $4.23B for the fiscal year ended Dec 31, 2025, with a net margin of 6.9%.
How much free cash flow does ABBV generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $19.03B minus capital expenditures of $1.21B produced free cash flow of $17.82B.
How much debt does AbbVie have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $58.94B, short-term debt of $8.55B and cash and equivalents of $5.23B.
ABBV pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts